Understanding antibiotic resistance in cystic fibrosis patients
Prevalence, Consequences and Mechanisms of Antibiotic Heteroresistance in Cystic Fibrosis
This study is looking at how some bacteria that can cause infections in people with cystic fibrosis become resistant to antibiotics, and it aims to find ways to make treatments work better by examining samples from patients at different times during their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10899534 on NIH RePORTER |
What this research studies
This research investigates how certain bacteria, particularly Pseudomonas aeruginosa, develop varying levels of resistance to antibiotics in cystic fibrosis patients. It focuses on understanding the mechanisms behind antibiotic heteroresistance, where some bacteria within a population are resistant while others are not. By studying sputum samples from patients during different treatment phases, the research aims to identify patterns that could improve antibiotic effectiveness and treatment outcomes. The approach combines clinical data with laboratory analysis to explore how these resistant bacteria behave over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are cystic fibrosis patients who experience chronic infections with Pseudomonas aeruginosa.
Not a fit: Patients without cystic fibrosis or those not infected with Pseudomonas aeruginosa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective antibiotic treatments for cystic fibrosis patients, improving their health outcomes.
How similar studies have performed: Previous research has indicated that understanding antibiotic resistance mechanisms can significantly improve treatment strategies, suggesting this approach has potential for success.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Singh, Pradeep K — University of Washington
- Study coordinator: Singh, Pradeep K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.